Literature DB >> 20868714

Structure-activity studies on novel polymyxin derivatives that carry only three positive charges.

Martti Vaara1, Timo Vaara.   

Abstract

Polymyxin B and colistin are pentacationic lipopeptides that possess a cyclic heptapeptide portion, a linear tripeptide portion, and a fatty acyl tail. They are used, in spite of nephrotoxicity, to treat infections caused by extremely multiresistant Gram-negative bacteria. We have recently developed novel derivatives, that carry three cationic charges only. Some of them, including NAB739, are directly antibacterial whereas others, including NAB7061, lack the direct activity but sensitize bacteria to other antibiotics. NAB739 and NAB7061 differ from the old polymyxins in their renal handling and have reduced affinity to kidney brush border membrane. To further study the structure-activity relationships, we here synthesized eight additional derivatives and tested their antibacterial activity. NAB751 carries methylheptanoyl as the fatty acyl instead of octanoyl in NAB739 and was as active as NAB739, whereas NAB750 with dodecanoyl was less active. NAB781 and NAB782 with the linear peptide portion Ser-DSer and Ser-Ser-DSer, respectively, were less active than NAB739 that carries Thr-DSer. NAB771 with Thr at position 8 in the cyclic portion (instead of Dab in NAB7061) and Thr-Dab as the linear peptide portion (instead of Thr-Abu in NAB7061), resembled NAB7061 in its activity. However, replacement of two Dab residues in the cyclic portion with Thr greatly decreased the activity, even though the loss of the cationic charges was compensated by introducing two Dab residues in the linear portion. These findings reveal that subtle structural modifications have a major effect on the antibacterial activity and that it is possible to design numerous tricationic polymyxin derivatives that are antibacterial.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868714     DOI: 10.1016/j.peptides.2010.09.010

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.

Authors:  Pamela Brown; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2017-01-11       Impact factor: 2.649

2.  Efficient production of polymyxin in the surrogate host Bacillus subtilis by introducing a foreign ectB gene and disrupting the abrB gene.

Authors:  Soo-Young Park; Soo-Keun Choi; Jihoon Kim; Tae-Kwang Oh; Seung-Hwan Park
Journal:  Appl Environ Microbiol       Date:  2012-03-30       Impact factor: 4.792

Review 3.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

4.  Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein.

Authors:  Mohammad A K Azad; Johnny X Huang; Matthew A Cooper; Kade D Roberts; Philip E Thompson; Roger L Nation; Jian Li; Tony Velkov
Journal:  Biochem Pharmacol       Date:  2012-05-12       Impact factor: 5.858

5.  Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.

Authors:  Angela Kavanagh; Soumya Ramu; Yujing Gong; Matthew A Cooper; Mark A T Blaskovich
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 6.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.